Ikena Oncology, Inc. (IKNA)
NASDAQ: IKNA · Real-Time Price · USD
1.720
0.00 (0.00%)
Nov 4, 2024, 4:00 PM EST - Market closed
Company Description
Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States.
Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway.
The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex.
Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Ikena Oncology, Inc.
| Country | United States |
| Founded | 2016 |
| IPO Date | Mar 26, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 43 |
| CEO | Mark Manfredi |
Contact Details
Address: 645 Summer Street, Suite 101 Boston, Massachusetts 02210 United States | |
| Phone | 857 273 8343 |
| Website | ikenaoncology.com |
Stock Details
| Ticker Symbol | IKNA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001835579 |
| CUSIP Number | 45175G108 |
| ISIN Number | US45175G1085 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mark Manfredi Ph.D. | President, Chief Executive Officer and Director |
| Dr. Jotin Marango M.D., Ph.D. | Chief Financial Officer and Head of Corporate Development |
| Rebecca Cohen | Vice President of Investor Relations, Corporate Strategy and Communication |
| Jeffrey Ecsedy Ph.D. | Chief Development Officer |
| Bob Lally | Senior Vice President of Finance and Operations |
| David Damphousse M.S. | Senior Vice President of Clinical Development Operations |
| Dr. Caroline Germa M.D., Ph.D. | Chief Medical Officer |
| Valdas Jurkauskas Ph.D. | Senior Vice President of Technical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 8, 2024 | 10-Q | Quarterly Report |
| Jul 12, 2024 | 8-K | Current Report |
| Jun 10, 2024 | 8-K | Current Report |
| May 28, 2024 | 8-K | Current Report |
| May 13, 2024 | 10-Q | Quarterly Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Mar 12, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2024 | 10-K | Annual Report |